Net profit of Epigral declined 37.00% to Rs 51.22 crore in the quarter ended September 2025 as against Rs 81.30 crore during the previous quarter ended September 2024. Sales declined 6.18% to Rs 587.36 crore in the quarter ended September 2025 as against Rs 626.06 crore during the previous quarter ended September 2024. ParticularsQuarter EndedSep. 2025Sep. 2024% Var. Sales587.36626.06 -6 OPM %22.4828.50 - PBDT111.96157.43 -29 PBT69.65125.18 -44 NP51.2281.30 -37 Powered by Capital Market - Live News

Epigral will hold a meeting of the Board of Directors of the Company on 10 November 2025.Powered by Capital Market - Live News

Net profit of Epigral rose 87.13% to Rs 160.69 crore in the quarter ended June 2025 as against Rs 85.87 crore during the previous quarter ended June 2024. Sales declined 6.86% to Rs 606.54 crore in the quarter ended June 2025 as against Rs 651.20 crore during the previous quarter ended June 2024. ParticularsQuarter EndedJun. 2025Jun. 2024% Var. Sales606.54651.20 -7 OPM %26.9427.07 - PBDT148.55164.41 -10 PBT107.01130.96 -18 NP160.6985.87 87 Powered by Capital Market - Live News

Epigral will hold a meeting of the Board of Directors of the Company on 2 August 2025.Powered by Capital Market - Live News

Epigral announced that the Annual General Meeting(AGM) of the company will be held on 28 June 2025.Powered by Capital Market - Live News